Get the Stockscreener App
4.91
1.03%
0.05
After Hours:
4.90
-0.010
-0.20%
Sellas Life Sciences Group Inc stock is traded at $4.91, with a volume of 2.65M.
It is up +1.03% in the last 24 hours and down -8.57% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$4.86
Open:
$4.9
24h Volume:
2.65M
Relative Volume:
0.38
Market Cap:
$881.75M
Revenue:
-
Net Income/Loss:
$-26.86M
P/E Ratio:
-19.98
EPS:
-0.2458
Net Cash Flow:
$-28.39M
1W Performance:
+1.03%
1M Performance:
-8.57%
6M Performance:
+125.23%
1Y Performance:
+280.62%
1-Day Range:
$4.82
$4.95
1-Week Range:
$4.53
$5.18
52-Week Range:
$1.26
$6.14
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
4.91 | 872.77M | 0 | -26.86M | -28.39M | -0.2458 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia Treatment - Insider Monkey
SELLAS Life Sciences Group (SLS) price target increased by 26.83% to 8.84 - MSN
SELLAS Life Sciences (SLS) to present SLS009 data at AACR 2026 - MSN
Patterns Watch: Is SELLAS Life Sciences Group Inc trading at a discountQuarterly Growth Report & AI Powered Market Entry Strategies - baoquankhu1.vn
Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN
SLS Stock Rises Premarket Ahead Of Cancer Summit This Month – Investors Eye Phase 3 AML Trial Milestone - Stocktwits
SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
Rally Mode: Can SELLAS Life Sciences Group Inc stock double in the next year2026 Valuation Update & Fast Moving Market Watchlists - baoquankhu1.vn
SLS stock rises premarket ahead of cancer summit this month – investors eye phase 3 AML trial milestone - MSN
Stock List: Research Stocks from Around the World - GuruFocus
History Review: Will SELLAS Life Sciences Group Inc benefit from seasonality2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Fed Watch: Whats the beta of SELLAS Life Sciences Group Inc stock2026 Analyst Calls & Daily Chart Pattern Signals - baoquankhu1.vn
SELLAS Rallies on Bullish Patterns — Despite Analyst Skepticism and Weak Fundamentals - Bitget
Levels Update: Is SELLAS Life Sciences Group Inc forming higher highs and higher lows2026 Year in Review & Verified Technical Signals - baoquankhu1.vn
SELLAS Life Sciences Group Stock Jumps 9.5% - National Today
SLS Technical Analysis | Trend, Signals & Chart Patterns | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
Stock Report: Will SELLAS Life Sciences Group Inc benefit from green energy policies2026 Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
FRA:RXK3 PB Ratio: 9.04 — 66% Above Median - GuruFocus
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail - MSN
SELLAS Life Sciences Group Stock Price Drops 7.7% - National Today
Gainers Report: Whats next for SELLAS Life Sciences Group Inc stock2026 Highlights & Low Risk Growth Stock Ideas - baoquankhu1.vn
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 7.7%Here's Why - MarketBeat
Why SELLAS Life Sciences Group (SLS) Is Down 8.3% After US$150 Million ATM Offering News - simplywall.st
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN
Sellas Life Sciences Secures Shelf Registration to Bolster Financial Flexibility - timothysykes.com
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade - MSN
A Look At SELLAS Life Sciences Group (SLS) Valuation After SLS009 Data And New Equity Offering Plans - simplywall.st
SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026 - Insider Monkey
MACD Signal: Is SELLAS Life Sciences Group Incs ROIC above industry average2026 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Vanguard (SLS) files amendment showing 0% beneficial ownership (warrants disclosed) - Stock Titan
5 Popular Penny Stocks on Robinhood to Buy - Insider Monkey
All you need to know about SELLAS Life Sciences Group, Inc. (SLS) rating upgrade to buy - MSN
All Essential Information Regarding SELLAS Life Sciences Group, Inc. (SLS) Rating Raised to Buy - Bitget
All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy - Yahoo Finance
SELLAS Life Sciences Group Inc (SLS) Stock News & Articles - 24/7 Wall St.
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sellas Life Sciences Group Inc Stock (SLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VAN NOSTRAND ROBERT L | Director |
Jun 12 '25 |
Buy |
1.48 |
10,000 |
14,800 |
20,400 |
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):